By Kate Greenwood
In Genetics
Jul 24th, 2014
1 Comment
By Layne Feldman Over the past year, two developments—one legal, and one economic—have hit Myriad Genetics, Inc. hard. These developments could have significant ramifications on the detection and treatment of cancer. First, last summer, the Supreme Court ruled that Myriad could not patent the isolated BRCA 1 and BRCA 2 genes that the company used […]...
By Gaia Bernstein
In Bioethics
Apr 17th, 2014
Cross Posted at HealthLawProf Blog 23andMe, the Internet genetic testing company, which offered genetic testing for health conditions and ancestry, has received extensive publicity in recent months. In November 2013, the FDA ordered 23andMe to stop marketing its health-related genetic test results to customers because their product is a “device”, which requires FDA app...
By Gaia Bernstein
In Ethics
Jul 22nd, 2010
[Ed. Note: We are pleased to welcome Professor Gaia Bernstein to Health Reform Watch. Articles about her recent scholarship, “Over-parenting,” may be found at the ABA Journal and The New York Times Magazine.] Genetic testing for adult onset diseases used to be mainly a medical service. In most cases a person who had a certain genetic disease […]...